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RESEARCH ARTICLE Open Access
Results from a blind and a non-blind randomised
trial run in parallel: experience from the Estonian
Postmenopausal Hormone Therapy (EPHT) Trial
Piret Veerus1*, Krista Fischer2, Matti Hakama3 and Elina Hemminki4, for The EPHT Trial
Abstract
Background: The Estonian Postmenopausal Hormone Therapy (EPHT) Trial assigned 4170 potential participants
prior to recruitment to blind or non-blind hormone therapy (HT), with placebo or non-treatment the respective
alternatives. Before having to decide on participation, women were told whether they had been randomised to
the blind or non-blind trial. Eligible women who were still willing to join the trial were recruited. After recruitment
participants in the non-blind trial (N = 1001) received open-label HT or no treatment, participants in the blind trial
(N = 777) remained blinded until the end of the trial. The aim of this paper is to analyse the effect of blinding on
internal and external validity of trial outcomes.
Methods: Effect of blinding was calculated as the hazard ratio of selected chronic diseases, total mortality and all
outcomes. For analysing the effect of blinding on external validity, the hazard ratios from women recruited to the
placebo arm and to the non-treatment arm were compared with those not recruited; for analysing the effect of
blinding on internal validity, the hazard ratios from the blind trial were compared with those from the non-blind
trial.
Results: The women recruited to the placebo arm had less cerebrovascular disease events (HR 0.43; 95% CI: 0.26-
0.71) and all outcomes combined (HR 0.76; 95% CI: 0.63-0.91) than those who were not recruited. Among women
recruited or not recruited to the non-treatment arm, no differences were observed for any of the outcomes
studied.
Among women recruited to the trial, the risk for coronary heart disease events (HR 0.77; 95% CI: 0.64-0.93),
cerebrovascular disease events (HR 0.66; 95%CI: 0.47-0.92), and all outcomes combined (HR 0.82; 95% CI: 0.72-0.94)
was smaller among participants in the blind trial than in the non-blind trial. There was no difference between the
blind and the non-blind trial for total cancer (HR 0.95; 95% CI: 0.64-1.42), bone fractures (0.93; 95% CI: 0.74-1.16),
and total mortality (HR 1.03; 95% CI: 0.53-1.98).
Conclusions: The results from blind and non-blind trials may differ, even if the target population is the same.
Blinding may influence both internal and external validity. The effect of blinding may vary for different outcome
events.
Trial registration: [ISRCTN35338757]
Keywords: Clinical trial, Blinding, Internal and external validity
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Background
Evidence from randomised controlled trials (RCTs) is an
essential source of information used by public health
policy makers as well as by clinicians and patients for
making treatment decisions. RCTs are conducted against
the backdrop of difficult methodological choices related
to the balance between internal validity (reliability of the
results) and external validity (generalisability) [1].
Internal validity is maximized by reducing bias by
using randomisation and blinding [2-4]. Most trial
methodology concentrates on issues related to internal
validity [5]. There are no general guidelines as to how
the external validity of randomised controlled trials
should be assessed [6-8]. Issues that potentially affect
external validity are considered to be the trial setting,
the selection of patients and clinicians, differences
between the trial protocol and routine practice, the rele-
vance of outcome measures and the length and comple-
teness of follow-up [9,10].
The Estonian Postmenopausal Hormone Therapy
(EPHT) Trial was carried out from 1999 to 2004 in
order to study the impact of postmenopausal hormone
therapy (HT) on bone fractures, cardiovascular diseases,
and cancer [11], on health services utilisation and health
care costs [12], on symptom reporting and quality of life
[13]. An additional aim was to study the impact of
blinding on recruitment [14], adherence [15] and trial
outcomes. Therefore, all potentially eligible participants
were simultaneously randomised to four trial arms
before signing the informed consent: blind and non-
blind HT arms, placebo arm or non-treatment arm.
The earlier published results from the EPHT Trial
with the follow-up until 2003 showed a difference
between the blind and non-blind trial in the number of
coronary heart disease events, cerebrovascular disease
events and all outcomes combined among recruited
women, but not for cancer and bone fractures [11].
Such observed differences in health outcomes between
the blind and the non-blind trial could not be explained
by the difference in adherence and contamination rates
which were similar in all trial arms. This generates a
hypothesis that blinding might influence validity of
results from placebo-controlled, double-blind rando-
mised trials.
In order to analyse the effect of blinding on external
validity of trial outcomes, the outcomes from recruited
women in the placebo and the non-treatment arms were
compared with those who were not recruited; also, the
numbers and the proportion of women with different
background characteristics recruited to blind and non-
blind trial were compared. For analysing the effect of
blinding on internal validity, the outcomes from the
blind trial were compared with those from the non-
blind trial, and in addition separately for blind versus
non-blind HT arm, and placebo versus non-treatment
arm. The follow-up period was extended up to year
2007.
Methods
Trial population
Information about the trial and a questionnaire were
mailed in 1998 to a sample of 39 713 women aged 45-
64 taken from the Estonian Population Registry and liv-
ing in two Estonian counties. The recruitment question-
naire included questions about willingness to join a
randomised trial and questions about health and social
status. Of the 14 743 women who returned the ques-
tionnaire, 6606 respondents were interested in partici-
pating, of which 4295 women were found to be eligible
according to the preliminary assessment, based on time
since menopause and other health data from the
questionnaires.
Randomisation
Randomisation was carried out before recruitment in
permuted blocks, each of a size 16 and each block of
the three trial clinics separately, at the National
Research and Development Centre for Welfare and
Health in Finland. The 125 women participating in the
pilot study were not included in the present analysis.
The 4170 eligible women who were willing to join the
main trial were randomised into blind and non-blind
arms and, at the same time, into treatment and control
arms (two-by-two design). Hence, there were four study
arms: 1) blind HT arm; 2) non-blind HT arm; 3) pla-
cebo arm and 4) non-treatment arm. Hereafter, blind
HT and placebo arm combined together will be named
blind trial, and non-blind HT and non-treatment arms
combined together non-blind trial.
Detailed descriptions of recruitment, inclusion and
exclusion criteria, trial treatment, adherence, follow-up
and trial outcomes as well as the content of information
leaflets and trial questionnaires have been published
elsewhere [11-17]. All participants gave written
informed consent. The study protocol was approved by
the Committee of Medical Ethics in Tallinn, Estonia and
by the Ethics Committee of the University Clinic of
Tampere, Finland. Data about randomised women who
were not recruited to the trial were acquired with a spe-
cial permission from the Estonian Data Protection
Agency.
Recruitment, trial treatment and adherence
The 4170 randomly assigned women were mailed an
invitation letter revealing whether they had been
assigned to the blind or the non-blind trial. The
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treatment allocation was enclosed in a non-transparent
sealed envelope with a woman’s study number and
name on it, and sent to the trial clinic. In the blind trial,
the women were told that they would be using either
hormone therapy or a placebo; in the non-blind trial,
they were told that they would be receiving hormone
therapy or non-treatment.
Final recruitment took place between January 1999
and December 2001. A total of 2323 women responded
to the mailed invitation to visit the trial doctor. After
this secondary assessment of eligibility, 1778 women
proved to be eligible and were willing to join the trial,
and their randomisation envelope was opened. The rea-
sons for ineligibility after secondary assessment have
been reported in detail elsewhere [12].
As a result, 404 women were recruited into the blind
HT arm, 373 into the placebo arm, 494 into the non-
blind HT arm and 507 into the non-treatment arm (Fig-
ure 1). None of the trial participants switched the trial
arm after randomisation. The women in the non-blind
HT arm were allocated to open-label HT, the women in
the non-treatment arm did not receive any drugs.
Adherence was assessed by the number of collected and
returned drugs and by the information from annual
questionnaires and weekly reports from the clinics.
Women taking more than 80% of the allocated drugs
were considered to be adherent, whilst women in the
non-treatment arm were considered to be adherent if
they were not taking hormone therapy for 80% of the
time. Data about prescribed HT use in the non-treat-
ment and placebo arms was obtained from the Estonian
Health Insurance Fund.
Intervention
During the treatment period, participating women and
health care providers were blinded to the treatment
assignment in the blind trial, but not in the non-blind
trial. The persons doing the linkages in registries, data
collectors and data analysts at research centres were
unaware of the treatment allocation, and remained
blinded also after the end of the trial. After publication
of the results from the Women’s Health Initiative
(WHI) trial, trial treatment was stopped gradually
between January and May 2004. Participants in the
blind trial received a letter containing information on
their treatment allocation within one month of their
final visit.
Outcome measures, data acquisition and analyses
performed
The randomised women were followed by annual lin-
kages to the Estonian Health Insurance Fund database,
the Estonian Cancer Registry database, and the Estonian
Mortality database using a person’s identity code. The
outcomes studied were coronary heart disease (I20-I25
according to the 10th revision of the International Clas-
sification of Diseases), [18] cancer (C00-C97), cerebro-
vascular disease (I60-I69), bone fractures (S12, S22, S32,
Assessed for eligibility
N=14743
Randomised
N=4170
Excluded N= 10573
Not meeting inclusion                         
criteria N=2311
Declined to participate 
N=8137
Pilot study
N=125
Blind HT N=1043 Non-blind HT N=1045 Placebo N=1040 Non-treatment N=1042
Allocated to 
intervention 
N=404
Not allocated 
to intervention 
N=639
Allocated to 
intervention
N=494
Not allocated 
to intervention 
N=551
Allocated to 
intervention 
N=373
Allocated to 
intervention 
N=507
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N=667
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N=535
Lost to f-up
N=4
Analysed 
N=404
Lost to f-up
N=1
Analysed 
N=639
Lost to f-up
N=1
Analysed 
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Lost to f-up
N= 2
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N=551
Lost to f-up
N=1
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N=2
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4
Figure 1 EPHT Trial flow chart.
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S42, S52, S62, S72, S82, S92), death from all causes and
all these combined. As the database of the Estonian
Health Insurance Fund was considered not fully com-
plete for the years 1999 and 2000, the first follow-up
date for all outcomes in the present analysis was January
1, 2001. The results of the analysis are reported here
separately for December 31, 2004 and December 31,
2007, as the last follow-up dates.
The Estonian Health Insurance Fund is the only orga-
nization in Estonia dealing with compulsory health
insurance [19]. It stores information about all health
care contacts, using an individual’s personal identifica-
tion code recorded in a centralised, computerised data-
base. The Health Insurance Fund pays for all health care
visits, diagnostic examinations, preventive and treatment
procedures, hospital stays, surgeries, technical aids dur-
ing or after surgery, and compensations for medicinal
products. All participants in the trial were insured. As
compensation to clinics depends on the transmission of
data to the central electronic database and not on the
diagnosis, we assume the probability of missing data in
the database of the Estonian Health Insurance Registry
to be minimal. The Estonian Cancer Registry database
has been validated for completeness of registration, with
the overall completeness of registration being 90.8% in
1998 [20].
The linkage with the Population Registry showed that
during the follow-up period nine women left from Esto-
nia (all among recruited participants: four in the blind
HT arm, one in the non-blind HT arm, one in the pla-
cebo arm, three in the non-treatment arm). Data about
these women in the registries might have been incom-
plete (Figure 1).
For analysing the effect of blinding on the selection
bias (i.e. external validity), the numbers of women
recruited to the blind and non-blind trial as well as
the proportion of women with different background
characteristics recruited to blind and non-blind trial
were compared. In addition, hazard ratios for differ-
ent outcome events among recruited versus non-
recruited women were calculated in the placebo arm
and in the non-treatment arm. The comparison was
restricted to the non-HT arms and the hazard ratios
between recruited and non-recruited women in the
blind and non-blind HT arms were not calculated in
order to exclude the effect of HT from the analysis of
blinding.
For analysing the effect of blinding on reporting bias,
observer bias, and placebo effect (i.e. internal validity),
the hazard ratios of outcome events among recruited
women in the blind and non-blind trial arms were com-
pared, separately until the year 2004 and 2007. During
the first period, participants in the HT arms were allo-
cated to trial treatment, and the participants in trial
arms as well as their physicians were blinded about
their treatment allocation. Blinding and trial treatment
was stopped in 2004. The analysis with the longer fol-
low-up period until 2007 was done to check if the dif-
ferences between the outcomes hold also after stopping
blinding and trial treatment.
Statistical analysis
The effect of blinding on the recruitment process was
first assessed by comparing the proportions of women
recruited to the blind and non-blind trial. Next, the pro-
portion of women with different background character-
istics was calculated in blind and non-blind trial arms
both among recruited and non-recruited women. The
baseline covariates used in the analysis (also in the
adjusted analysis for the outcomes) were age, education,
living place (corresponding to the clinic of recruitment),
smoking status, and time since menopause.
The outcome data were analysed by time-to-event
methods. For each of the target disease groups, the
number of days from recruitment to the first diagnosis
in this group, as registered in the Health Insurance
Fund database, the Estonian Cancer Registry database,
or in the Estonian Mortality database was used as the
outcome variable. Time to diagnosis was censored for
women who did not have the corresponding diagnosis
registered during follow-up. Person-years at risk were
calculated from January 1, 2001 to December 31, 2007
(and from January 1, 2001 to December 31, 2004) or to
the outcome event studied or to death whichever came
first.
Cumulative hazard plots based on the Kaplan-Meier
method were obtained for descriptive comparison of
outcome distributions in blind and non-blind trial, sepa-
rately for recruited and non recruited women.
Comparison of clinical outcomes between blind and
non-blind trial for all randomised women was per-
formed (the intention-to-treat analysis for the effect of
blinding), using the Cox proportional hazards modelling.
Clinical outcomes were then compared between blind
and non-blind trial separately for recruited and non-
recruited women. For recruited women, separate com-
parisons were done for HT and non-HT arms, as well
as the combined analysis, stratified by HT assignment.
Interaction for blinding and treatment among recruited
women was tested for, but not included in the model.
In addition, comparison of outcomes between recruited
and non-recruited women in the placebo and non-treat-
ment arms was carried out.
For each of the comparison, both crude and adjusted
hazard ratios with 95% confidence intervals were
obtained, using Cox proportional hazards modelling.
The software used for analyses was R for Windows,
version 2.8.1 [21].
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Results
Effect of blinding on external validity of clinical outcomes
From the 2087 women randomised to the non-blind
trial, and from the 2083 women randomised to the
blind trial, 1001 (47.9%) were recruited to the non-blind
and 777 (37.3%) to the blind trial arms (p < 0.0001 for
the difference). From the 2392 women not recruited to
the trial, eight women had deceased before the follow-
up period (one in blind HT arm, two in non-blind HT
arm, two in placebo arm and three in non-treatment
arm), and two women not recruited to the placebo arm
had lost health insurance (Figure 1).
The mean follow-up time from January 1, 2001 to the
earliest of December 31, 2007 or loss of follow-up
(death or leaving the country), was 6.89 years (minimal
0.11 years, maximal 7.0 years). When December 31,
2004 was used as the last follow-up date, the mean fol-
low-up time was 3.97 years (minimal 0.11 years, maxi-
mal 4.0 years).
From the background characteristics recorded in the
recruitment questionnaire, age, education, living place
(clinic of recruitment), smoking status and time since
menopause appeared to influence the probability of
being recruited. Younger women were more eager to
join the trial. University education increased consider-
ably the recruitment probability in non-blind trial, with
possibly only a weak effect in blind trial. Current smo-
kers were less interested to join the non-blind trial,
there was no significant difference in that respect in the
blind trial. The university clinic appeared to be more
successful in recruiting women to blind trial than the
other clinics, with no difference found for non-blind
trial (Table 1).
At the end of the first trial year, participants were
asked in a questionnaire what was their guess about the
treatment they were receiving. In the blind HT arm,
48% of participants remained unclear about their treat-
ment allocation, and 49% in the placebo arm. The
proportion of women supposing to receive active treat-
ment was 35% in the blind HT arm and 19% in the pla-
cebo arm. The number of women supposing to receive
placebo was 13% in the blind HT arm and 28% in the
placebo arm. About 4% of participants in both arms of
the blind trial stated to be indifferent regarding the
treatment allocation (Table 2). The reasons for the
guesses were not queried.
Adherence rate was similar in blind and non-blind HT
arms, but lower in the placebo arm. However, the use of
placebo prevented contamination, because more women
in the non-treatment arm than in the placebo arm
started using prescribed HT [15]. The proportion of
adherent women in the HT arms throughout the whole
trial was 30%, and 23% in the placebo arm. In the non-
treatment arm, 8% of women started using prescribed
HT, and 4% in the placebo arm. Adherence and con-
tamination rates in different arms throughout the trial
have been reported earlier [15].
The intention-to-treat analysis among all randomised
women did not show differences between hazard rates
for any outcome event between women randomised to
blind and non-blind trial (crude HR between blind and
non-blind trial for coronary heart disease was 0.91 (95%
CI: 0.81-1.02), for cancer 0.93 (95% CI: 0.73-1.20), for
cerebrovascular disease 0.97 (95% CI: 0.80-1.18), for
bone fractures 1.07 (95% CI: 0.93-1.23), for total
Table 1 Proportion of women with different background characteristics among recruited and non-recruited women in
blind and non-blind trial arms, EPHT Trial
Background characteristics Blind (n = 2083) Non-blind (n = 2087)
Recruited
(n = 777)
Non-
recruited (n = 1306)
p-value Recruited
(n = 1001)
Non-recruited
(n = 1086)
p-value
Age > 64 yrs 5.5% 9.3% 0.002 6.8% 10.1% 0.008
University education 31.8% 29.5% 0.28 33.5% 25.1% < 0.0001
Recruited in
the university
clinic
(living in Tartu
or Tartu
county)
33.3% 27.2% 0.003 29.8% 29.2% 0.77
Current smoker 15.2% 16.7% 0.39 14.7% 20.1% 0.002
> 10 yrs since menopause 28.6% 32.7% 0.06 27.9% 34.7% 0.001
Table 2 Participants’ guess on treatment allocation
(number and proportion of women) in different trial
arms at the end of the first trial year, the EPHT Trial
Don’t
know
Correct
guess
Incorrect
guess
Don’t
care
Blind HT 414 300 117 36
N = 867 48% 35% 13% 4%
Blind
placebo
375 213 144 33
N = 765 49% 28% 19% 4%
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mortality 1.10 (95% CI: 0.78-1.54), and for all outcomes
combined 0.98 (95% CI: 0.90-1.07). The results were
similar in the adjusted analysis and in separate analyses
for HT and non-HT arms.
The difference for all outcomes combined between the
women recruited and those not recruited was bigger in
the blind trial than in non-blind trial, both in treatment
and non-treatment arms (Figures 2, 3).
The comparison of different outcome events among
recruited and non-recruited women in the placebo arm
showed a difference as regards to cerebrovascular dis-
ease events (HR 0.43; 95% CI: 0.26-0.71) and all out-
comes combined (HR 0.76; 95% CI: 0.63-0.91). There
was no difference in outcome events among women
recruited or not recruited to the non-treatment arm for
any of the outcomes studied (Table 3). The sensitivity
analysis of the stroke and cerebral infarction events only
(ICD-10 codes I60-I64) with the follow-up until 2007
showed a difference among recruited and non-recruited
women both in the placebo arm (HR 0.19; 95% CI: 0.04-
0.83) and non-treatment arm (HR 0.43; 95% CI: 0.20-
0.93). The risk of stroke and cerebral infarction only did
not differ between women who were recruited to the
blind and non-blind trial (HR 0.51; 95% CI: 0.22-1.15).
Effect of blinding on internal validity of clinical outcomes
Among all the 1778 women finally recruited to the trial
and with the follow-up until 2007, there was a smaller
risk of coronary heart disease events (HR 0.77; 95% CI:
0.64-0.93), cerebrovascular disease events (HR 0.66; 95%
CI: 0.47-0.92) and all outcomes combined (HR 0.82;
95% CI: 0.72-0.94) in the blind trial than in the non-
blind trial. The combined hazard ratio for total mortality
between women recruited to the blind and those
recruited to the non-blind trial arms did not differ (HR
1.03; 95% CI: 0.53-1.98), with seven deaths in the pla-
cebo arm, eleven in the non-treatment arm, nine in the
blind HT, and nine in the non-blind HT arm (Table 4).
For women recruited to the placebo arm there was a
smaller risk of cerebrovascular disease events (HR 0.51;
95% CI: 0.30-0.86) and for all outcomes combined (HR
0.81; 95% CI: 0.67-0.98), in comparison with the women
recruited to the non-treatment arm. For women recruited
to the blind HT arm, there was a smaller risk for coronary
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Figure 2 All outcomes: effect of recruitment on control arms.
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heart disease events (HR 0.77; 95% CI: 0.60-1.00) than for
women recruited to the non-blind HT arm.
Among women not recruited to the trial, there were
no differences between the blind or non-blind trial for
any of the outcomes studied (Table 4). Adjustment for
differences in background characteristics did not change
the results (data not shown).
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Figure 3 All outcomes: effect of recruitment on HT arms.
Table 3 Crude and adjusted hazard ratios for different outcome events among recruited versus non-recruited women
in placebo and non-treatment arms, EPHT Trial, 2001 to 2007
Outcome Placebo arm Non-treatment arm
Recruited vs non-recruited Recruited vs non-recruited
HR (95% CI), crude HR (95% CI),
adjusted*
HR (95% CI), crude HR (95% CI), adjusted*
Coronary heart disease 0.81
(0.62-1.04)
0.80
(0.62-1.03)
1.02
(0.82-1.28)
1.06
(0.84-1.33)
Cancer 1.00
(0.58-1.70)
0.97
(0.57-1.66)
0.71
(0.42-1.20)
0.75
(0.44-1.29)
Cerebrovascular disease 0.43
(0.26-0.71)
0.44
(0.27-0.73)
0.86
(0.59-1.26)
0.90
(0.61-1.31)
Bone fractures 0.89
(0.67-1.18)
0.88
(0.67-1.17)
1.28
(0.97-1.69)
1.30
(0.98-1.72)
Total mortality 0.51
(0.22-1.19)
0.51
(0.23-1.22)
0.72
(0.33-1.55)
0.80
(0.34-1.74)
All outcomes combined 0.76
(0.63-0.91)
0.75
(0.63-0.91)
1.05
(0.89-1.25)
1.09
(0.92-1.30)
*adjusted for age, living-place, education, smoking status, and time since menopause
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If restricting the analysis with the year 2004 when
unblinding occurred after stopping trial treatment, there
were less cancer cases (HR 0.53; 95% CI: 0.31-0.91), less
cerebrovascular disease events (HR 0.57; 95% CI: 0.38-
0.84) and fewer outcomes combined (HR 0.78; 95% CI:
0.66-0.91) among women recruited to the blind trial in
comparison with those recruited to the non-blind trial.
Among women recruited to the placebo arm, there were
less cerebrovascular disease events (HR 0.34; 95% CI:
0.18-0.67) and all outcomes combined (HR 0.75; 95%
CI: 0.59-0.93) until the end of 2004 than among women
in the non-treatment arm (Table 4).
Effect of blinding on subjective outcomes, and use of
health services
For subjective outcomes, the detailed results have been
published elsewhere: as regards symptom reporting and
quality of life, there were no differences between the
blind and the non-blind HT arms or placebo and non-
treatment arms [13]. The use of health services did not
differ between the blind HT arm and the placebo arm,
but the number of health care visits was much higher in
the non-blind HT arm than in the non-treatment arm
[12].
Discussion
Summary of the key findings
As far as we know, there are no earlier reports on the
impact of blinding on trial outcomes. The experience
from the EPHT Trial showed a difference between the
blind and non-blind trial in the number of coronary
heart disease events, cerebrovascular disease events and
all outcomes combined among recruited women, but
not for cancer, bone fractures and total mortality,
Table 4 Crude hazard ratios for different outcome events among recruited women in blind versus non-blind trial
arms, EPHT Trial: data presented for the periods from 2001 to 2004 and from 2001 to 2007
Outcome/
Time period
Recruited women Non-recruited women
Blind vs
non-blind HT,
HR (95% CI)
Placebo vs
non-treatment,
HR (95% CI)
Blind vs
non-blind trial,
HR (95% CI)*
Blind vs non-
blind trial,
HR (95% CI)
Coronary heart disease
2001-2004 0.89
(0.66-1.19)
0.75
(0.55-1.02)
0.82
(0.66-1.01)
1.06
(0.89-1.26)
2001-2007 0.77
(0.60-1.00)
0.78
(0.60-1.01)
0.77
(0.64-0.93)
1.01
(0.87-1.18)
Cancer
2001-2004 0.59
(0.29-1.23)
0.47
(0.21-1.04)
0.53
(0.31-0.91)
0.94
(0.66-1.33)
2001-2007 0.77
(0.44-1.33)
1.23
(0.68-2.23)
0.95
(0.64-1.42)
0.90
(0.65-1.24)
Cerebrovascular disease
2001-2004 0.80
(0.48-1.33)
0.34
(0.18-0.67)
0.57
(0.38-0.84)
1.24
(0.92-1.68)
2001-2007 0.80
(0.52-1.24)
0.51
(0.30-0.86)
0.66
(0.47-0.92)
1.15
(0.90-1.46)
Bone fractures
2001-2004 0.69
(0.43-1.10)
0.94
(0.65-1.37)
0.83
(0.62-1.11)
1.10
(0.87-1.38)
2001-2007 0.96
(0.69-1.35)
0.90
(0.67-1.21)
0.93
(0.74-1.16)
1.17
(0.97-1.42)
Total mortality
2001-2004 0.73
(0.18-3.07)
0.27
(0.03-2.32)
0.51
(0.16-1.63)
0.90
(0.52-1.67)
2001-2007 1.22
(0.49-3.08)
0.86
(0.33-2.22)
1.03
(0.53-1.98)
1.02
(0.69-1.52)
All outcomes combined
2001-2004 0.81
(0.65-1.02)
0.75
(0.59-0.93)
0.78
(0.66-0.91)
1.10
(0.97-1.25)
2001-2007 0.83
(0.69-1.02)
0.81
(0.67-0.98)
0.82
(0.72-0.94)
1.08
(0.97-1.21)
*stratified by treatment
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indicating that blinding may influence validity of results,
and the effect may vary for different outcomes.
Strengths and limitations of the study
Randomisation of eligible participants was unconven-
tionally carried out before joining the trial in order to
study the impact of blinding on recruitment. This
resulted in losses among randomised participants. Prob-
ability of being recruited was found to be dependent on
several background characteristics with the effect being
different for women randomised to blind or non-blind
trial. This may have caused a different selection bias in
the blind and non-blind trial as compared to the target
population, grounded on a preference effect [22]. From
the background characteristics studied, the participant’s
education, smoking status and the trial setting (living in
the university clinic area) influenced the probability to
be recruited and might have thus influenced the external
validity of outcomes due to blinding. Higher recruitment
rates to the blind trial in the university clinic may indi-
cate that trials carried out in university clinics recruit
different participants than trials in other clinics.
The comparison between recruited and non-recruited
women in the placebo arm indicated a smaller risk
among recruited women for cerebrovascular diseases
and all outcomes combined. In the non-treatment arm,
no difference between recruited and non-recruited
women was observed. This suggests that the differences
between blind and non-blind trial can be explained by
differential post-randomisation selection: the women
who joined the blind trial may have had smaller baseline
risks for outcome events than those who joined the non
blind trial. In this case, comparison of the risks of out-
come events among non-recruited women who were
assigned to blind and non- blind trial should result in
hazard ratios that are approximately inverse of the cor-
responding hazard ratios in recruited women. Here,
however, this is only partly the case, as for coronary
heart disease and cerebrovascular disease the hazard
ratios for non-recruited women are not significant and
the point estimates are considerably smaller than the
inverse of the corresponding hazard ratios in recruited
women. This supports the hypothesis that the differ-
ences among recruited women in blind and non-blind
trial cannot be entirely explained by differential selec-
tion, and that blinding may influence also internal
validity.
Analysis of outcome events among all randomised
women did not show any differences between trial arms.
So there is no clear evidence of a “causal effect” of
blinding - the risk of outcome events for any particular
women being altered by random assignment to either
blind or non blind trial. However, for coronary heart
disease the difference is of borderline significance and
confidence intervals for other outcome events are very
wide - so we cannot entirely exclude the possibility of a
causal effect of blinding.
Among recruited women, there were less cerebrovas-
cular disease events and all outcomes combined in the
placebo arm than in the non-treatment arm, and less
coronary heart disease events in the blind than in the
non-blind HT arm. A separate analysis with a shorter
follow-up period until trial participants and physicians
became unblinded showed less cancer cases, cerebrovas-
cular disease events and all outcomes combined in blind
trial. The differences in the outcomes between the
shorter and longer follow-up period support the hypoth-
esis that in addition to selection bias, there is a potential
reporting and/or observer bias in blinded studies. For
cancer, blinding may have caused a delay in diagnosis;
for cerebrovascular disease, the additional sensitivity
analysis for only ‘hard’ outcomes like stroke and brain
infarction did not show a difference between blind and
non-blind trial among recruited women.
We also note that the difference in clinical outcomes
between the placebo and non-treatment arm was incon-
sistent for various outcomes which were studied. These
differences pinpoint the importance of the behavioural
component, the attitudes of physicians and patients,
sometimes called the placebo effect [23]. In the
Women’s Health Initiative (WHI) trial, where 44.4% of
women on active treatment were unblinded (versus 6.8%
on placebo), [24] detection bias was estimated to have
caused higher detection rates of otherwise unrecognised
acute myocardial infarction among HT users [25].
The results of the WHI trial were not discussed widely
in Estonia, and the preterm stopping of that trial did not
receive much media coverage, if any. All trial partici-
pants received a thorough medical check-up at the clo-
sure visit. Therefore, we presume that the preterm
stopping of the trial did not influence further care-seek-
ing by trial participants.
Conclusions
Implications in the context of the evidence
The clinical usefulness of the results from clinical trials
depends on their external and internal validity. In every-
day practice, patients and physicians are not blinded. In
contrast with the earlier studies, the experience from
the EPHT trial did not show an exaggerated treatment
effect within the non-blind trial in comparison with the
blind trial [26,27]. Patients have preferences that are
related to the design of a clinical trial. However, the
trial design is also related to its purpose. Blind settings
are preferable to test the efficacy of a new treatment
whereas the effectiveness of treatment and the use of
health care resources may be more properly studied
within non-blind settings [28]. Our study demonstrates
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that non-blind randomised trials may be suitable for
postmarketing trials or health services research in gen-
eral. Meta-analyses incorporating data both from clinical
trials and observational studies should take into account
the possible difference in the outcomes not only due to
randomisation, but also due to blinding.
Unanswered questions and future research directions
In summary, our findings suggest that the participants
as well as the outcomes in the blind trials may be differ-
ent than those in non-blind trials, even if the target
population is the same [29]. The effect of blinding may
vary for different outcome events. How much of this
results from selection bias for women with different
background characteristics, from difference in seeking
medical advice due to health symptoms because of
knowing the treatment or not, or from a delay in diag-
noses due to the effect of blinding on the attitudes of
physicians and patients needs further research.
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